Loperamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Loperamide: From Diarrhea to Acute Contagious Conjunctivitis
One-Sentence Summary
Loperamide is a well-known peripheral mu-opioid receptor agonist used for symptomatic control of diarrhea (this evidence pack contains no confirmed original-indication or regulatory text — the drug is currently not marketed in this jurisdiction). The TxGNN model’s top prediction is Acute Contagious Conjunctivitis, but this candidate has 0 clinical trials and 0 publications supporting it, and is explicitly flagged in the source rationale as a likely knowledge-graph clustering artifact rather than a real pharmacological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack (no licenses on file; loperamide is generically known as an antidiarrheal agent) |
| Predicted New Indication | Acute Contagious Conjunctivitis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 (model prediction only, no trials or literature) |
| Market Status | Not marketed (未上市) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available for loperamide in this evidence pack (flagged as a High-severity data gap). Based on general pharmacological knowledge, loperamide acts on peripheral mu-opioid receptors in the gut wall to reduce intestinal motility and secretion — a mechanism confined to the gastrointestinal tract with no known pathway relevant to ocular surface or conjunctival inflammation.
The top-ranked prediction, acute contagious conjunctivitis, has no supporting clinical trials or literature in this pack. The accompanying rationale explicitly assesses it as a false positive: there is no plausible pharmacological link between a peripheral antidiarrheal agent and an infectious eye condition, and the score is judged to result from the TxGNN disease-embedding space clustering multiple unrelated conjunctivitis subtypes together (ranks 3, 5–9 are all conjunctivitis variants with near-identical scores of ~0.996, several sharing the exact same score value — a signature of embedding collinearity rather than independent evidence).
Notably, the two candidates with the most literature support in this batch — amebic dysentery and gastroduodenitis — are not genuine repurposing opportunities either. The available literature describes antimotility agents like loperamide as contraindicated in invasive/infectious diarrhea (risk of toxic megacolon, delayed pathogen clearance) and reports a case of loperamide-induced respiratory depression in severe GI inflammation. None of the 10 ranked predictions in this pack currently clear the bar for a positive repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered for Acute Contagious Conjunctivitis.
Literature Evidence
Currently no related literature available for Acute Contagious Conjunctivitis.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications and DrugBank DDI data are both marked as data gaps in this pack — DG001 “TFDA 仿單警語/禁忌” is flagged Blocking severity and must be resolved before any S1 safety evaluation.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (acute contagious conjunctivitis) has zero supporting evidence and is assessed as a likely TxGNN embedding-cluster false positive rather than a genuine signal. No candidate across the full top-10 list reaches a positive recommendation — the two candidates with literature support (amebic dysentery, gastroduodenitis) are contraindicated or carry documented safety risk rather than efficacy support.
To proceed, the following is needed:
- TFDA label warnings/contraindications (Blocking data gap DG001) before any safety evaluation can begin
- Confirmed mechanism of action (DG002) to properly assess mechanistic plausibility
- Independent validation of the TxGNN conjunctivitis cluster (ranks 1, 3, 5–9) to rule out a systematic embedding artifact before any of these candidates are pursued further
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.